NCT04533399: A trial that was reported late by Novavax
This trial has reported, although it was 110 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04533399 |
|---|---|
| Title | A Phase 2A/B, Randomized, Observer-blinded, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in South African Adult Subjects Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 17, 2020 |
| Completion date | Dec. 7, 2021 |
| Required reporting date | Dec. 7, 2022, midnight |
| Actual reporting date | March 27, 2023 |
| Date last checked at ClinicalTrials.gov | Aug. 22, 2025 |
| Days late | 110 |